Drugs / HRS-3095
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07686484 | Jul → Oct 2026 expected | chronic idiopathic urticaria | Atridia Pty Ltd. | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07230418 | Nov 2025 → Apr 2026 | chronic idiopathic urticaria | Chengdu Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07613866 | Jul → Dec 2026 expected | chronic urticaria | Chengdu Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-3095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07686484 ↗ |
| Route | Oral | “Oral HRS-3095 tablet.” NCT07230418 ↗ |